Abstract
Launching a new drug on the market is an extremely time-consuming and expensive process. The total costs from the lab bench to the patients bedside are in the range of $800 million for each new compound. Innovative preclinical assays are urgently needed to select the most promising drug candidates. High-throughput molecular screening does not provide information on the effects on cellular functions. Testing on animals is expensive, ethically controversial, and poorly predictive of the response in humans. Conventional two-dimensional (2D) cellular assays do not accurately reflect the drug response in vivo. To overcome these limitations, biotechnologists are developing three-dimensional (3D) cultures. 3D cultures provide more accurate compound screening and can eliminate toxic and ineffective substances at an early stage. Moreover, 3D cultures can accomplish the 3R agenda (refinement, reduction, and replacement) for the replacement of toxicity testing on animals. We provide an up-to-date overview on the patents in the field.
Keywords: 3D cell culture, extracellular matrix, ECM, cellular spheroid, microcarrier culture, microfluidic culture, organotypic culture, drug discovery, toxicity screening, 3R agenda
Recent Patents on Biotechnology
Title: Three-Dimensional Tissue Models for Drug Discovery and Toxicology
Volume: 3 Issue: 2
Author(s): Francesco Pampaloni, Ernst H. K. Stelzer and Andrea Masotti
Affiliation:
Keywords: 3D cell culture, extracellular matrix, ECM, cellular spheroid, microcarrier culture, microfluidic culture, organotypic culture, drug discovery, toxicity screening, 3R agenda
Abstract: Launching a new drug on the market is an extremely time-consuming and expensive process. The total costs from the lab bench to the patients bedside are in the range of $800 million for each new compound. Innovative preclinical assays are urgently needed to select the most promising drug candidates. High-throughput molecular screening does not provide information on the effects on cellular functions. Testing on animals is expensive, ethically controversial, and poorly predictive of the response in humans. Conventional two-dimensional (2D) cellular assays do not accurately reflect the drug response in vivo. To overcome these limitations, biotechnologists are developing three-dimensional (3D) cultures. 3D cultures provide more accurate compound screening and can eliminate toxic and ineffective substances at an early stage. Moreover, 3D cultures can accomplish the 3R agenda (refinement, reduction, and replacement) for the replacement of toxicity testing on animals. We provide an up-to-date overview on the patents in the field.
Export Options
About this article
Cite this article as:
Pampaloni Francesco, Stelzer H. K. Ernst and Masotti Andrea, Three-Dimensional Tissue Models for Drug Discovery and Toxicology, Recent Patents on Biotechnology 2009; 3 (2) . https://dx.doi.org/10.2174/187220809788700201
DOI https://dx.doi.org/10.2174/187220809788700201 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine Promiscuous Binding Nature of Sh3 Domains to their Target Proteins
Protein & Peptide Letters AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies
Current HIV Research Look Into My Onco-forest - Review of Plant Natural Products with Anticancer Activity
Current Topics in Medicinal Chemistry Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design A Novel Hydroxysteroid-Sulfating Cytosolic Sulfotransferase, SULT3 ST3, from Zebrafish: Identification, Characterization, and Ontogenic Study
Drug Metabolism Letters Novel Concepts for Anti-Infective Activity of Cytokines, Chemokines and Diverse Agents
Recent Patents on Anti-Infective Drug Discovery Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives
Current Topics in Medicinal Chemistry The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Anticancer Immunotherapy in Combination with Proapoptotic Therapy
Current Cancer Drug Targets Inactivated- or Killed-Virus HIV/AIDS Vaccines
Current Drug Targets - Infectious Disorders Post-Docking Optimization and Analysis of Protein-Ligand Interactions of Estrogen Receptor Alpha using AMMOS Software
Current Computer-Aided Drug Design Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Novel Pentablock Copolymer Based Nanoparticles Containing Pazopanib: A Potential Therapy for Ocular Neovascularization
Recent Patents on Nanomedicine Effective Prodrug Liposome and Conversion to Active Metabolite
Current Drug Metabolism Local Gene Delivery for Cancer Therapy
Current Gene Therapy